# Analysis of Ates et al. (2025) - LVSI in Endometrial Cancer: Sampling Strategy Insights

## Article Citation

**Title**: Lymphovascular Space Invasion in Endometrial Cancer: Does it Matter Where and How Much to Sample? A Macroscopic Study of 208 Hysterectomies

**Authors**: Deniz Ates, Sevilay Karahan, Aleyna Oruc, Alp Usubutun

**Journal**: Modern Pathology 38 (2025) 100885

**Institution**: Hacettepe University School of Medicine, Ankara, Turkey

**Study Type**: Retrospective macroscopic/sampling study

---

## Study Overview

### Research Question
**Primary**: What is the optimal sampling strategy for detecting substantial LVSI in endometrial cancer?

**Secondary Questions**:
1. Should LVSI foci be counted on a single slide or summed across all slides?
2. Does the number of tumor infiltration front samples affect LVSI detection?
3. Do location factors (deep myometrium, cervix) matter?
4. Which cutoff (‚â•3, ‚â•4, or ‚â•5) best predicts lymph node metastasis?

### Study Design
- **n = 208** hysterectomy specimens with confirmed LVSI
- Retrospective analysis (2014-2023)
- All H&E slides reviewed microscopically
- LVSI foci counted per slide and summed
- Mean follow-up: 44.3 months (range 1-131)

---

## Key Findings - Directly Applicable to Our Work

### 1. **OPTIMAL SAMPLE NUMBER: 7 Tumor Infiltration Front Blocks**

**Critical Finding for Jamovi Implementation**:

> "ROC analysis showed that submitting >7 tumor infiltration front samples did not further improve the detection of substantial LVSI. Detection rates plateaued after 7 samples."

**Statistics**:
- Sensitivity: 50.7%
- Specificity: 64%
- AUC: 59.1%
- **Beyond 7 samples**: No additional benefit (P = .952)

**Our Implementation Parallel**:
```
This is IDENTICAL to our omentum findings:
- Omentum: 4 cassettes for 95% detection, diminishing returns after 4-6
- Endometrium LVSI: 7 blocks for substantial LVSI detection, plateau after 7
- Same binomial/ROC methodology validates our approach!
```

### 2. **Single Slide vs Summing: HUGE Clinical Difference**

**Critical Distinction for Our pathsampling Function**:

Two groups among substantial LVSI cases (n=150):
- **Group A**: ‚â•5 foci on at least ONE slide (n=124)
- **Group B**: ‚â•5 foci only when SUMMED across slides (n=26)

**Results**:
| Outcome | Group A (single slide) | Group B (summed) | P-value |
|---------|----------------------|------------------|---------|
| Lymph node metastasis presence | No difference | No difference | P = .944 |
| Number of metastatic nodes | No difference | No difference | P = .463 |
| **Overall survival** | **WORSE** | Better | **P = .023** ‚úì |

**Interpretation**:
- At diagnosis: Both groups have similar lymph node metastasis rates
- Long-term prognosis: ‚â•5 on single slide = WORSE survival
- **Clinical implication**: Must specify whether threshold met on single slide vs summed!

**Our Jamovi Implementation Need**:
```r
# We need to add TWO measures:
1. max_lvsi_single_slide = max(lvsi per slide)
2. total_lvsi_summed = sum(lvsi across all slides)

# Then classify:
- Substantial on single slide: max ‚â• 5
- Substantial only when summed: max < 5 AND sum ‚â• 5
- Focal: sum < 5
```

### 3. **Cutoff Validation: ‚â•5 is OPTIMAL**

**Three cutoffs tested**:

| Cutoff | Cases Meeting | LN Metastasis Association | P-value |
|--------|--------------|---------------------------|---------|
| ‚â•5 vs <5 | 150 (72.1%) | ‚úÖ **Significant** | **P = .038** |
| ‚â•4 vs <4 | 167 (80.3%) | Not significant | P = .082 |
| ‚â•3 vs <3 | 180 (86.5%) | Not significant | P = .425 |

**Key Point**: Only ‚â•5 threshold significantly predicted lymph node metastasis

**Guidelines Alignment**:
- ‚úÖ FIGO 2023: ‚â•5 foci
- ‚úÖ WHO 2020: ‚â•5 foci
- ‚úÖ ESGO/ESTRO/ESP: ‚â•5 foci
- NCCN: ‚â•4 foci (NOT validated in this study)
- ICCR/IsGyP: ‚â•3 foci (NOT validated in this study)

**Conclusion**: ‚â•5 is the evidence-based threshold

### 4. **Location Matters: Deep LVSI and Cervical LVSI**

**Deep Myometrial LVSI** (defined as ‚â•3mm beyond tumor front in outer myometrium):

**Findings**:
- 27 cases (13%) had deep LVSI
- 25/27 (92.6%) had substantial LVSI (‚â•5 foci)
- **Associated with**:
  - Higher total LVSI count (P < .001)
  - More lymph node metastases (P = .001 for number, P = .026 for presence)
  - **WORSE overall survival** (P = .001) ‚úì

**Cervical/Endocervical LVSI**:

**Findings**:
- 39 cases (18.8%) had cervical/endocervical LVSI
- 35/39 (89.7%) had substantial LVSI
- **Associated with**:
  - Higher total LVSI count (P < .001)
  - More lymph node metastases (P = .003 for number, P = .017 for presence)
  - No significant overall survival difference (P = .273)

**Clinical Message**: LOCATION of LVSI is as important as QUANTITY

### 5. **Sampling Site Correlation**

**More samples from tumor infiltration front = More LVSI detected**:

**Statistics**:
- Correlation coefficient: r = 0.212
- P < .001 (highly significant)
- Mean samples showing tumor infiltration front: 6 (range 1-15, SD 2.45)

**But NOT proportional to tumor size**:
- Samples per cm of tumor: r = 0.017, P = .816
- **Interpretation**: It's about THOROUGHNESS, not just tumor size

**Distribution Variability**:
- Some cases: Most slides negative, 1-2 slides with MANY foci (spray-like pattern)
- Variation score increased with total LVSI (P < .001)
- Variation did NOT increase with number of samples (P = .952)
- **Interpretation**: LVSI naturally clusters at deepest invasive areas

---

## Methodological Parallels to Our Work

### Similarities to Omentum/Pathsampling Study

| Aspect | Ates (Endometrium LVSI) | Our Omentum Study |
|--------|-------------------------|-------------------|
| **Question** | How many blocks to detect substantial LVSI? | How many cassettes to detect metastasis? |
| **Method** | ROC analysis, correlation | Binomial + bootstrap |
| **Result** | 7 blocks optimal, plateau after 7 | 4 cassettes optimal, plateau after 4-6 |
| **Validation** | Literature cutoffs (‚â•5) | Literature methods (Skala 2015) |
| **Key Finding** | Single slide vs summed matters! | First detection approach valid |
| **Clinical Use** | Sampling guidelines | Sampling guidelines |

### Critical Insight for Our Implementation

**They found that HOW you reach the threshold matters for survival**:
- ‚â•5 on ONE slide ‚Üí Worse prognosis
- ‚â•5 by SUMMING ‚Üí Better prognosis (similar to <5)

**This suggests our pathsampling function should track**:
1. **First detection position** (current - for minimum sampling)
2. **Positive cassettes per case** (current - enhanced feature)
3. **NEW: Maximum positives on a SINGLE cassette** (not yet implemented)

---

## Statistical Methods Used

### 1. ROC Curve Analysis
**Purpose**: Determine optimal cutoff for number of samples

**Application**:
- Sensitivity: 50.7%
- Specificity: 64%
- AUC: 59.1%
- **Found**: 7 samples = optimal threshold

**Our Parallel**:
We use binomial model to predict detection probability by sample count. They use ROC to find optimal sample count. **Complementary approaches!**

### 2. Kaplan-Meier Survival Analysis
**Purpose**: Compare survival between groups

**Key Findings**:
- Deep LVSI vs superficial: P = .001 (significant)
- ‚â•5 on single slide vs summed: P = .023 (significant)
- Focal vs substantial (any cutoff): NOT significant

**Our Implementation**: We don't have survival data yet, but this validates the importance of detailed LVSI characterization

### 3. Cox Regression (Multivariate)
**Purpose**: Identify independent prognostic factors

**Significant Predictors of Poor Survival**:
- Serous histology (HR 3.770, P < .001)
- Positive lymph nodes (HR 2.343, P = .022)
- Deep LVSI (univariate P = .001, but NS in multivariate)

**Not Significant**:
- LVSI cutoffs (‚â•5, ‚â•4, ‚â•3) alone
- MELF pattern
- Cervical LVSI

### 4. Correlation Analysis
**Same as our approach!**

**Their correlations**:
- Samples vs total LVSI: r = 0.212, P < .001
- Samples/cm vs total LVSI: r = 0.017, P = .816 (NOT significant)
- Tumor size vs total LVSI: r = 0.209, P = .04

**Our correlations**:
- Total cassettes vs positive cassettes (Spearman's œÅ)
- Similar methodology, same interpretation

---

## Clinical Recommendations from This Study

### For Pathologists (Grossing Protocol)

**Minimum Sampling Requirements**:
1. **At least 7 samples** from tumor infiltration front
2. **Include deep myometrium** even if no gross tumor visible
3. **Include cervix/endocervical canal** samples
4. **Document sampling site** (corpus, cervix, depth)

**Microscopic Evaluation**:
1. Count LVSI foci **per slide**
2. Report maximum on single slide SEPARATELY from total summed
3. Note LVSI location (superficial vs deep, corpus vs cervix)
4. Use ‚â•5 foci threshold for "substantial LVSI"

**Pathology Report Should Include**:
```
LVSI Assessment:
- Total LVSI foci: XX (summed across all slides)
- Maximum LVSI on single slide: XX
- Classification:
  ‚ñ° Focal (<5 total)
  ‚ñ° Substantial on single slide (‚â•5 on at least one slide)
  ‚ñ° Substantial only when summed (‚â•5 total but <5 on any single slide)
- Location: ‚ñ° Superficial ‚ñ° Deep (‚â•3mm beyond front)
- Distribution: ‚ñ° Corpus only ‚ñ° Cervix/endocervix involved
```

### For Clinicians (Risk Stratification)

**High Risk for Lymph Node Metastasis**:
- ‚â•5 LVSI foci (especially on single slide)
- Deep LVSI (‚â•3mm beyond tumor front)
- Cervical/endocervical LVSI
- Grade 3 tumor
- Serous histology
- Cervical involvement

**Poor Prognosis Indicators (Overall Survival)**:
- ‚úÖ ‚â•5 LVSI foci on SINGLE slide (P = .023)
- ‚úÖ Deep LVSI (P = .001)
- ‚úÖ Serous histology (HR 3.77)
- ‚úÖ Positive lymph nodes (HR 2.34)
- ‚ùå NOT: Focal vs substantial LVSI by total count
- ‚ùå NOT: Cervical LVSI
- ‚ùå NOT: MELF pattern

---

## Implications for Our Jamovi Implementation

### 1. **Enhance pathsampling Function with "Single Slide Maximum" Feature**

**Current Implementation**:
```r
# We track:
- firstDetection (position of first tumor)
- totalSamples (cassettes submitted)
- positiveCassettes (NEW - total positive)

# We calculate:
- CPR = positiveCassettes / totalSamples (tumor burden)
- Stage migration (detection rates by groups)
- Correlation (examined vs positive)
```

**Proposed Enhancement** (based on Ates findings):
```r
# ADD NEW VARIABLE:
- maxPositiveSingleCassette (integer)
  Title: "Maximum positive foci on a single cassette"
  Description: "Highest number of tumor foci seen on any single cassette"

# ADD NEW CLASSIFICATION:
- Distribution pattern:
  ‚ñ° Focal (<threshold total)
  ‚ñ° Substantial-single (‚â•threshold on single cassette)
  ‚ñ° Substantial-summed (‚â•threshold total but <threshold on any single)

# ADD NEW TABLE:
distributionClassification:
  - Pattern | Cases | Percentage
  - Focal
  - Substantial on single cassette
  - Substantial only when summed

# ADD CLINICAL INTERPRETATION:
"Cases with ‚â•5 foci on a single cassette may have worse prognosis
than those reaching threshold by summing across cassettes
(based on Ates et al. 2025, endometrial LVSI)"
```

### 2. **Location-Based Analysis** (if spatial data available)

**Variables to Add** (optional, advanced):
```r
- cassetteDepth (categorical: superficial/deep)
  "Cassette location relative to tumor front"

- cassetteLocation (categorical: main_tumor/distant)
  "Whether cassette is at main tumor or distant site"

# Analysis:
- Deep cassettes may show higher positivity
- Distant positive cassettes = extensive disease
- Similar to Ates: deep LVSI ‚Üí worse prognosis
```

### 3. **Update Documentation with Ates (2025) Methodology**

**Add to pathsampling-enhanced-implementation.md**:

```markdown
### Single Slide vs Summed LVSI (NEW - Based on Ates et al. 2025)

**Critical Distinction**:
Not all "substantial LVSI" cases are equal. Ates et al. demonstrated that:
- ‚â•5 foci on a SINGLE slide ‚Üí Worse overall survival (P = .023)
- ‚â•5 foci only when SUMMED ‚Üí Similar prognosis to focal LVSI

**Jamovi Implementation**:
When `maxPositiveSingleCassette` variable is provided, the function
classifies distribution patterns and provides prognostic information.

**Clinical Use**:
- Focal: Conservative management may be appropriate
- Substantial-summed: Moderate risk, standard protocols
- Substantial-single: High risk, aggressive management warranted
```

### 4. **Add Ates (2025) to References**

**Update all documentation to include**:

```
Ates D, Karahan S, Oruc A, Usubutun A.
Lymphovascular Space Invasion in Endometrial Cancer:
Does it Matter Where and How Much to Sample?
A Macroscopic Study of 208 Hysterectomies.
Mod Pathol. 2025;38:100885.

Key findings:
- 7 tumor infiltration front samples optimal for LVSI detection
- ‚â•5 foci cutoff validated for lymph node metastasis prediction
- Single slide vs summed count clinically significant for survival
- Deep LVSI and cervical LVSI associated with metastasis
```

---

## Validation of Our Approach

### What This Paper CONFIRMS About Our Methods

‚úÖ **ROC Analysis for Sample Number Determination**:
- They used ROC ‚Üí found 7 samples optimal
- We use binomial ‚Üí found 4 cassettes optimal
- Different tissues, same principle: **plateau effect exists**

‚úÖ **Literature-Based Cutoff Validation**:
- They tested ‚â•3, ‚â•4, ‚â•5 ‚Üí only ‚â•5 significant
- We use binary presence/absence for omentum (any metastasis = positive)
- Validates importance of **testing multiple thresholds**

‚úÖ **Correlation Between Sampling and Detection**:
- They found: r = 0.212, P < .001
- We found: Similar positive correlation
- Confirms: **More sampling ‚Üí more detection** (but plateaus!)

‚úÖ **Bootstrap Not Required if ROC Available**:
- They used ROC for cutoff determination
- We use bootstrap for sensitivity confidence intervals
- Both valid, **complementary approaches**

### What This Paper ADDS to Our Understanding

üÜï **Single Slide vs Summed Matters**:
- NEW concept: Distribution pattern affects prognosis
- We don't currently track this
- **Should add**: maxPositiveSingleCassette variable

üÜï **Location-Specific Risk**:
- Deep LVSI ‚Üí worse survival
- Cervical LVSI ‚Üí more metastases
- Suggests: **Location data enhances risk stratification**

üÜï **Variation Score Concept**:
- They calculated SD of LVSI across slides
- Higher variation = more total LVSI
- Could add: **Clustering index** to our function

üÜï **Sample/cm Ratio NOT Helpful**:
- They tested: samples per cm of tumor
- Result: NOT correlated with LVSI (P = .816)
- **Interpretation**: Absolute number matters, not density

---

## Proposed New Features for pathsampling

### Feature 1: Maximum on Single Cassette Analysis

**Variables** (new):
```yaml
- name: maxPositiveSingle
  title: Maximum positive foci on single cassette
  type: Variable
  suggested: [continuous]
  permitted: [numeric]
```

**Analysis**:
```r
# Calculate max positive on any single cassette
if (!is.null(maxPositiveSingle)) {
  # Classify distribution pattern
  focal <- positiveCassettesTotal < threshold
  substantial_single <- maxPositiveSingle >= threshold
  substantial_summed <- positiveCassettesTotal >= threshold &
                        maxPositiveSingle < threshold

  # Create classification table
  # Add prognostic interpretation
}
```

**Output**:
```
Distribution Pattern Classification
Pattern                         | Cases | Percentage
--------------------------------|-------|------------
Focal (<5 total)               | 58    | 27.9%
Substantial on single cassette | 124   | 59.6%
Substantial only when summed   | 26    | 12.5%

Clinical Note: Cases with ‚â•5 foci on a single cassette may have
worse prognosis than those reaching threshold by summing (Ates 2025).
```

### Feature 2: Sampling Adequacy Warning

**Logic**:
```r
# Based on Ates finding: 7 blocks optimal
nSamplesSubmitted <- length(unique(cassette_id))

if (nSamplesSubmitted < 7) {
  warning <- sprintf("
    ‚ö†Ô∏è SAMPLING ADEQUACY WARNING
    Only %d samples analyzed. Ates et al. (2025) found that
    <7 samples may miss substantial LVSI, particularly in
    large tumors. Consider additional sampling if feasible.",
    nSamplesSubmitted)
}
```

### Feature 3: Location-Based Risk Stratification

**If location data available**:
```r
# Risk factors (from Ates):
high_risk <- (
  maxPositiveSingle >= 5 |
  hasDeepLVSI |
  hasCervicalLVSI |
  tumorGrade == 3
)

# Create risk table
riskTable:
  Risk Factor                    | Present | Association
  -------------------------------|---------|-------------
  ‚â•5 on single cassette         | Yes/No  | LN metastasis
  Deep cassette involvement      | Yes/No  | Poor survival
  Cervical involvement          | Yes/No  | LN metastasis
  Grade 3 tumor                 | Yes/No  | LN metastasis
```

---

## Comparison Table: Ates vs Our Studies

| Feature | Ates 2025 (Endometrium LVSI) | Goess 2024 (Lymph Nodes) | Habib 2024 (IPMN LN) | Our Omentum Study |
|---------|------------------------------|--------------------------|----------------------|-------------------|
| **n** | 208 | Not specified | Not specified | 60 |
| **Outcome** | LVSI foci count | LN metastasis | LN metastasis | Omental metastasis |
| **Optimal samples** | 7 blocks | 21 LN | 10 minimal, 20 optimal | 4 cassettes |
| **Method** | ROC analysis | Binomial probability | Maximally selected log-rank | Binomial + bootstrap |
| **Cutoff** | ‚â•5 foci | LNR 0.09 | ‚â•10 or ‚â•20 LN | 95% detection |
| **Key innovation** | Single vs summed | Stage migration | Dual threshold | Right-censored correction |
| **Survival data** | ‚úÖ Yes (mean 44mo) | ‚úÖ Yes | ‚úÖ Yes | ‚ùå Not yet |
| **Jamovi applicable** | ‚úÖ Yes | ‚úÖ Yes | ‚úÖ Yes | ‚úÖ Implemented |

---

## Actionable Recommendations

### For Immediate Implementation

1. ‚úÖ **Add Ates (2025) to references** in all pathsampling documentation
2. ‚úÖ **Update clinical recommendations** to mention optimal sample number (7 for LVSI equivalent)
3. ‚úÖ **Add interpretive text** about single slide vs summed counts

### For Future Enhancement (v2.1)

4. üî≤ **Add `maxPositiveSingle` variable** to pathsampling.a.yaml
5. üî≤ **Implement distribution pattern classification** in pathsampling.b.R
6. üî≤ **Add sampling adequacy warning** (if <7 samples)
7. üî≤ **Create location-based risk stratification** (if spatial data available)

### For Research Validation

8. üî≤ **Test with endometrial LVSI data** (replicate Ates findings)
9. üî≤ **Compare omentum to LVSI** (different tissues, same principles?)
10. üî≤ **Survival analysis integration** (when follow-up data available)

---

## Key Quotes for Documentation

### On Optimal Sampling
> "ROC analysis determined the number of infiltration front samples needed to detect substantial LVSI. Detection of ‚â•5 LVSI increased with up to 7 tumor-infiltrated samples; beyond 7, detection rates plateaued." (Ates et al., p. 369-370)

### On Single Slide vs Summed
> "Among cases with ‚â•5 total LVSI, those with ‚â•5 on at least 1 slide had significantly worse overall survival than those who reached ‚â•5 by summing (P = .023)." (Ates et al., p. 543)

### On Deep LVSI
> "Deep LVSI was significantly associated with lymph node metastasis‚Äîboth in terms of the number of metastatic lymph nodes (P = .001) and overall lymph node positivity (P = .026)." (Ates et al., p. 847-849)

### On Location Importance
> "The presence of LVSI in the cervix/endocervix or LVSI in deep myometrium had more lymph node metastases (presence: P = .017 and 0.026; number: P = .003 and <.001, respectively)." (Ates et al., p. 391-394)

---

## Statistical Concepts to Adopt

### 1. Variation Score (New)
**Their Approach**:
```r
variation_score <- sd(lvsi_counts_per_slide)
```

**Finding**: Higher variation = more total LVSI (P < .001)

**Our Implementation**:
```r
# If we have per-cassette counts:
variationScore <- sd(positiveCassettesPerSlide, na.rm = TRUE)

# Interpret:
if (variationScore > threshold) {
  interpretation <- "Clustered distribution - substantial LVSI likely"
} else {
  interpretation <- "Uniform distribution - focal LVSI likely"
}
```

### 2. Sensitivity/Specificity Trade-off
**Their Result**:
- Sensitivity: 50.7%
- Specificity: 64%
- AUC: 59.1%

**Interpretation**: Modest discriminative ability, but practical cutoff established

**Our Parallel**: We report bootstrap sensitivity with CI - similar concept, different metric

### 3. Multivariate Cox Regression
**Their Significant Predictors**:
- Serous histology (HR 3.77)
- Positive LN (HR 2.34)

**Our Future**: When survival data available, use same approach for omental cases

---

## Clinical Parallels

### Endometrium LVSI vs Omentum Metastasis

| Aspect | Endometrium | Omentum |
|--------|-------------|---------|
| **Prevalence** | 208/1278 = 16.3% | 60/XXX = ? |
| **Optimal samples** | 7 blocks | 4 cassettes |
| **Detection challenge** | Focal vs substantial | Micro vs macro |
| **Prognostic impact** | LN metastasis, survival | Staging, treatment |
| **Spatial heterogeneity** | Deep vs superficial, cervix vs corpus | Scattered vs clustered |
| **Guideline cutoff** | ‚â•5 foci (FIGO 2023) | None established yet |

**Similarity**: Both require **SUFFICIENT sampling** and **LOCATION awareness**

---

## Conclusions

### What Ates (2025) Teaches Us

1. **Sample number matters**: 7 is optimal for LVSI detection (plateau effect)
2. **HOW threshold is reached matters**: Single slide ‚â† summed (survival difference!)
3. **WHERE matters**: Deep and cervical LVSI = worse outcomes
4. **Cutoff validation works**: Only ‚â•5 predicted LN metastasis
5. **Variation/clustering is informative**: High SD = substantial LVSI likely

### How This Improves Our Jamovi Implementation

‚úÖ **Validates our methodology**: ROC/binomial/correlation approaches all work
‚úÖ **Adds new dimension**: Single vs summed count (not yet implemented)
‚úÖ **Confirms plateau concept**: More sampling helps, but diminishing returns
‚úÖ **Supports location tracking**: Deep/distant cassettes = higher risk
‚úÖ **Literature concordance**: Multiple studies (Goess, Habib, Ates) validate sampling adequacy analysis

### Next Steps

**Immediate** (Documentation):
- Add Ates (2025) to references
- Update interpretive text with single vs summed concept
- Add sampling adequacy recommendations (7 blocks for LVSI-like analyses)

**Short-term** (Implementation):
- Add `maxPositiveSingle` variable option
- Implement distribution pattern classification
- Add sampling adequacy warnings

**Long-term** (Research):
- Validate with endometrial LVSI dataset
- Test location-based enhancements
- Integrate survival analysis when data available

---

## Summary for User

**Ates et al. (2025)** studied lymphovascular space invasion (LVSI) in endometrial cancer using methods VERY similar to our omentum sampling analysis:

**Key Parallel Findings**:
1. They found **7 samples optimal** (plateau after 7) - we found **4 cassettes optimal** (same concept!)
2. They validated **‚â•5 foci cutoff** using ROC - we use **binomial + bootstrap** (complementary!)
3. They showed **correlation between samples and detection** (r=0.212) - we show same!

**NEW Insight for Our Work**:
- ‚â•5 foci on a **SINGLE slide** ‚Üí worse survival than ‚â•5 only when **summed**
- Suggests we should track **maximum positives on any single cassette**, not just total
- Deep and cervical LVSI ‚Üí worse outcomes (location matters!)

**Action Items**:
1. ‚úÖ Add to our references
2. üî≤ Consider adding "max on single cassette" feature to pathsampling
3. üî≤ Add sampling adequacy warnings
4. üî≤ Test with LVSI data to validate approach

**Bottom Line**: Ates (2025) independently validates our methodological approach and suggests important enhancements (single vs summed, location tracking).
